^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | berzosertib (M6620) (ATR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase 2 single-arm study of berzosertib in combination with irinotecan in patients with progressive TP53 mutant gastric and gastro-esophageal junction cancer.
Published date:
05/25/2023
Excerpt:
Although the primary endpoint of ORR was not met, the combination of irinotecan and berzosertib in patients with TP53-mutated G/GEJ adenocarcinoma was well-tolerated and demonstrated anti-tumor activity comparable to other agents with published later-line data.
Secondary therapy:
irinotecan
DOI:
10.1200/JCO.2023.41.16_suppl.4044
Trial ID:
